The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Canaccord Genuity on November 6, 2025. The analyst firm set a price target for $24.00 expecting ZVRA to rise to within 12 months (a possible 189.68% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Zevra Therapeutics (NASDAQ:ZVRA) was provided by Canaccord Genuity, and Zevra Therapeutics maintained their buy rating.

There is no last upgrade for Zevra Therapeutics

There is no last downgrade for Zevra Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zevra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zevra Therapeutics was filed on November 6, 2025 so you should expect the next rating to be made available sometime around November 6, 2026.

While ratings are subjective and will change, the latest Zevra Therapeutics (ZVRA) rating was a maintained with a price target of $25.00 to $24.00. The current price Zevra Therapeutics (ZVRA) is trading at is $8.29, which is out of the analyst’s predicted range.